Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zynquista

Sanofi reception

Nasacort approval cements Sanofi’s OTC ambitions

Can sell allergy spray directly to consumers in US

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

- PMLiVE

Sanofi pulls Lyxumia’s US filing

Says will resubmit diabetes drug for FDA approval in 2015

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

- PMLiVE

Sanofi vaccine against GI ‘superbug’ starts phase III

Aims to protect against Clostridium difficile

Sanofi reception

FDA panel backs OTC use of Sanofi’s allergy drug

Says Nasacort AQ can be sold without prescription

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links